Regenxbio RGNX reported its Q3 earnings results on Thursday, November 3, 2022 at 07:05 AM.
Here's what investors need to know about the announcement.
Earnings
Regenxbio missed estimated earnings by 19.86%, reporting an EPS of $-1.75 versus an estimate of $-1.46.
Revenue was down $4.26 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.05 which was followed by a 2.21% increase in the share price the next day.
Here's a look at Regenxbio's past performance:
Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
---|---|---|---|---|
EPS Estimate | -1.53 | -1.32 | 4.71 | -1.08 |
EPS Actual | -1.58 | -1.58 | 6.67 | -1.37 |
Revenue Estimate | 26.79M | 29.21M | 271.74M | 41.46M |
Revenue Actual | 32.65M | 22.22M | 398.65M | 30.77M |
To track all earnings releases for Regenxbio visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.